SCHEMBL650134

SCHEMBL650134

COc1ccc(/N=C2/NC(=O)/C(=C/c3cnc(N(C=O)C4CC4)s3)S2)c(C(=O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.39
DAPK3 O43293 1/20 0.39
DYRK3 O43781 1/20 0.39
PIM1 P11309 1/20 0.39
CSNK2A1 P68400 1/20 0.39
DYRK1A Q13627 1/20 0.39
PIM3 Q86V86 1/20 0.39
HIPK2 Q9H2X6 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
CSNK1G1 Q9HCP0 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
PTPN11 Q06124 2/20 0.38
ALOX15 P16050 1/20 0.38
PTGS2 P35354 1/20 0.38
KIF11 P52732 2/20 0.37
MAPT P10636 2/20 0.37
POLB P06746 2/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650076 0.89 MAPT (0.44) AKR1B1DAPK3DYRK3PIM1CSNK2A1
SCHEMBL650769 0.81 MAPT (0.39) MEN1KMT2APTPN11ALOX15PTGS2
SCHEMBL650135 0.81 ABL1 (0.43) AKR1B1DAPK3DYRK3PIM1CSNK2A1
SCHEMBL651308 0.81 ABL1 (0.43) AKR1B1DAPK3DYRK3PIM1CSNK2A1
SCHEMBL653362 0.81 MAPT (0.45) MEN1KMT2AALOX15PTGS2MAPT
SCHEMBL652694 0.80 GSK3B (0.47) DAPK3DYRK3PIM1CSNK2A1DYRK1A
SCHEMBL653599 0.78 MAPT (0.40) PIM1PIM3PIM2MEN1KMT2A
SCHEMBL653447 0.78 MAPT (0.39) MEN1KMT2AMAPTPOLBHPGD
SCHEMBL653505 0.78 MAPT (0.40) PIM1PIM3PIM2MEN1KMT2A
SCHEMBL648825 0.77 DYRK3 (0.36) DYRK3PIM1PIM3PIM2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 AKR1B1 1750/4885DAPK3 285/4885DYRK3 1808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.